Literature DB >> 6360329

Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.

E Boven, J B Vermorken, H van Slooten, H M Pinedo.   

Abstract

This study concerns the history of a male patient with hormone-producing adrenal cortical carcinoma. Six months after resection of the primary tumor, lymph node metastases were detected and treatment with o,p'-DDD [1,1 dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane] (Lysodren/mitotane) was started. After 2 years, a complete histologically proven response was confirmed at laparotomy and is still sustained 2 years after the discontinuation of treatment. As a consequence of insufficient steroid replacement the patient suffered bouts of adrenal insufficiency. After 1 year of treatment, the measurement of the plasma levels of o,p'-DDD showed an accumulation of the drug. At that time, progressive major central nervous system toxicity occurred, which proved to be reversible on discontinuation of the treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6360329     DOI: 10.1002/1097-0142(19840101)53:1<26::aid-cncr2820530107>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 2.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 3.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

4.  Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane.

Authors:  I Ilias; M Alevizaki; G Philippou; E Anastasiou; A Souvatzoglou
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

5.  Adrenocortical carcinoma. An immunohistochemical comparison with renal cell carcinoma.

Authors:  M R Wick; D L Cherwitz; R C McGlennen; L P Dehner
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

6.  Adrenal cortical carcinoma in Norway, 1970-1984.

Authors:  J A Søreide; K Brabrand; S O Thoresen
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

Review 7.  Treatment of adrenocortical carcinoma: contemporary outcomes.

Authors:  David Y T Chen; R Ernest Sosa; Douglas S Scherr
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

8.  Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.

Authors:  R Bonacci; A Gigliotti; E Baudin; N Wion-Barbot; P Emy; M Bonnay; A F Cailleux; I Nakib; M Schlumberger
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.